Inclusion Criteria:

          1. The patient had multiple myeloma (according to the updated IMWG diagnostic
             criteria)Active (symptomatic) myeloma

          2. Refractory and recurrent multiple myeloma Refractory definition: 1) treated with at
             least second-line bortezomib or lenalidomide 2) determined by the clinician Definition
             of recurrence: refer to NCCN clinical guidelines for multiple myeloma (2016. V2),
             including recurrence after transplantation.

          3. Age: 18 to 80 years old;

          4. The expected survival time was more than 3 months;

          5. ECoG score 0-2 (refer to Annex 2)

          6. Hemoglobin (HB)≥80g/L; absolute neutrophil count (ANC)>1×10^9/L; platelet
             count(PLT)≥50×10^9/L.

        Those who voluntarily participated in the experiment and signed informed consent.

        Exclusion Criteria:

          1. High risk organ involvement patients: tumor invasion of central nervous system,
             gastrointestinal tract,lung,pericardium,one of the major vessels;

          2. Those who have graft-versus-host reaction and need to use immunosuppressants, or who
             have autoimmune diseases;

          3. Chemotherapy or radiotherapy was used within 3 days before blood collection;

          4. Patients who used systemic steroids within 5 days before blood collection (except
             those who have recently or are currently using inhaled steroids);

          5. The patients who used drugs to stimulate the production of bone marrow hematopoietic
             cells within 5 days before the blood collection period;

          6. Those who have previously used any gene therapy products;

          7. History of epilepsy or other central nervous system diseases;

          8. New York Heart Association (NYHA) grade III or above (refer to Annex 3) (for patients
             with heart disease, this assessment is required);

          9. Creatinine > 1.5 times normal upper limit, ALT / AST>3 times normal upper limit or
             bilirubin >2 times normal upper limit;

         10. Active hepatitis B or hepatitis C virus, HIV or other uncured active infections;

         11. Pregnant or lactating women;

         12. Those who suffer from other uncontrolled diseases are not suitable to join the study;
             Any situation that the researchers believe may increase the risk of subjects or
             interfere with the test results.